Jcm Free Full Text Rituximab Use In Warm And Cold Autoimmune
![jcm Free Full Text Rituximab Use In Warm And Cold Autoimmune jcm Free Full Text Rituximab Use In Warm And Cold Autoimmune](https://www.mdpi.com/jcm/jcm-09-04034/article_deploy/html/images/jcm-09-04034-g002.png)
Jcm Free Full Text Rituximab Use In Warm And Cold Autoimmune Autoimmune hemolytic anemia is a rare condition characterized by destruction of red blood cells with and without involvement of complement. it is associated with significant morbidity and mortality. in warm autoimmune hemolytic anemia, less than 50% of patients remain in long term remission following initial steroid therapy and subsequent therapies are required. cold agglutinin disease is a. Search text. search type . add circle outline jcm. volume 9. issue 12. 10.3390 jcm9124034. version notes. murakhovskaya i. rituximab use in warm and cold.
![jcm Free Full Text Rituximab Use In Warm And Cold Autoimmune jcm Free Full Text Rituximab Use In Warm And Cold Autoimmune](https://www.mdpi.com/jcm/jcm-09-04034/article_deploy/html/images/jcm-09-04034-g001.png)
Jcm Free Full Text Rituximab Use In Warm And Cold Autoimmune Autoimmune hemolytic anemia (aiha) is a rare disorder with an estimated incidence of 0.8–3 per 10 5 year in adults, and prevalence of 17 per 100,000 [ 1, 2, 3 ]. aiha can present at any age but it is more common in adults with a peak incidence between 50 and 70 years [ 1 ]. aiha is characterized by the production of antibodies directed. Rituximab is the preferred therapy for steroid refractory warm autoimmune hemolytic anemia (waiha) and as part of the first and second line treatment of cold agglutinin disease. this article reviews the mechanism of action of rituximab and the current literature on its role in the management of primary and secondary warm autoimmune hemolytic. Autoimmune hemolytic anemia is a rare condition characterized by destruction of red. blood cells with and without involvement of complement. it is associated with significant morbidity. and. Autoimmune hemolytic a nemia (aiha) is a rare disorder with an estimated incidence of 0 .8 –3. per 10 year in adults, and prevalence of 17 per 100,000 [1 3]. aiha can present at any age but it.
Comments are closed.